NDA 216974 · Entasis Therap
Xacduro (Copackaged)
Durlobactam Sodium, Sulbactam Sodium · Intravenous
NovelPriority reviewCDER novel approval, May 23, 2023: To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
Last checked: Nov 20, 2026Latest source record: May 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 23, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 2023 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
- XACDURO (COPACKAGED) · DURLOBACTAM SODIUM EQ 500MG BASE/VIAL; DURLOBACTAM SODIUM EQ 500MG BASE/VIAL; SULBACTAM SODIUM EQ 1GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Durlobactam" as an intervention, any sponsor and status, largest first.
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform TrialPivotal-lookingNot yet recruiting
The University of QueenslandAcademic, hospital or other
NCT07485010 · 300 participants (planned) · Start Apr 2027 · Primary completion Apr 2031
Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection and 16 more · For: Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections and 1 more
- Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus ComplexPivotal-lookingCompleted
Entasis TherapeuticsIndustry
NCT03894046 · 207 participants · Start Sep 5, 2019 · Primary completion Jul 26, 2021
Drug: Sulbactam; Durlobactam and 2 more · For: Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia and 2 more
Sites: Chicago, Illinois; Shreveport, Louisiana; Cincinnati, Ohio · 90 sites in all
- Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy SubjectsPivotal-lookingCompleted
Entasis TherapeuticsIndustry
NCT02971423 · 124 participants · Start Oct 2016 · Primary completion Jun 1, 2017
Drug: ETX2514; Placebo and 2 more · For: Acinetobacter Baumannii Infection
Sites: Melbourne, Australia
Innoviva Specialty TherapeuticsIndustry
NCT06801223 · 48 participants (planned) · Start Dec 30, 2026 · Primary completion May 5, 2028
Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) and 2 more · For: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Sites: Los Angeles, California; San Diego, California; Greenville, North Carolina · 4 sites in all
Entasis TherapeuticsIndustry
NCT03985410 · 32 participants · Start May 23, 2019 · Primary completion Jul 24, 2019
Drug: ETX2514; Placebo and 1 more · For: Acinetobacter Baumannii-calcoaceticus Complex Infections
Sites: Baltimore, Maryland
Entasis TherapeuticsIndustry
NCT03303924 · 30 participants · Start Aug 21, 2017 · Primary completion Oct 17, 2017
Drug: ETX2514 and sulbactam · For: Healthy
Sites: Phoenix, Arizona
Entasis TherapeuticsIndustry
NCT04018950 · 8 participants · Start Jun 21, 2019 · Primary completion Jul 26, 2019
Drug: ETX2514; 14C-ETX2514 · For: Acinetobacter Baumannii-calcoaceticus Complex Infections
Sites: Baltimore, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, et al. · Lancet Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
- Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen.
Dubey V, Reza N, Hope W · Clin Microbiol Rev 2025 · Systematic Review
- Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).
Miller AA, Moussa SH, McLeod SM · Antimicrob Agents Chemother 2024 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.
Zhang X, Zhang C, Lv M, et al. · Front Cell Infect Microbiol 2025 · Systematic Review
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.
Dan MO, Tǎlǎpan D · Front Microbiol 2024 · Systematic Review
- Resistance of Acinetobacter baumannii Complex Clinical Isolates to Sulbactam-Durlobactam: A Systematic Review of Data from In Vitro Studies.
Falagas ME, Romanos LT, Ragias D, et al. · Pathogens 2025 · Systematic Review
Sponsor: Entasis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.